

We claim

1. A pharmaceutical composition, comprising a therapeutically effective amount of each of linezolid, bedaquiline, and pretomanid, and optionally
5 pyrazinamide, or a pharmaceutically acceptable salt of each thereof, and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition as claimed in claim 1, wherein linezolid is at a dosage of 100 mg/kg.
10

3. The pharmaceutical composition as claimed in claim 1, wherein linezolid is at a dosage of 50 mg/kg.

4. The pharmaceutical composition as claimed in claim 1,
15 wherein the pharmaceutical composition is in the form of a plurality of unit dosages, the plurality of unit dosages collectively comprising the therapeutically effective amount of each of linezolid, bedaquiline and pretomanid, and optionally pyrazinamide or a pharmaceutically acceptable salt of each thereof.


20 5. The pharmaceutical composition as claimed in claim 1, wherein the pharmaceutical composition is in the form of a plurality of unit dosages, the plurality of unit dosages collectively comprising 600 mg or 1200 mg linezolid, 200 to 400 mg bedaquiline, 100 to 200 mg pretomanid, and optionally pyrazinamide, or a pharmaceutically acceptable salt of each thereof.

25 6. The pharmaceutical composition as claimed in claim 1, wherein the pharmaceutical composition is in the form of a single unit dosage, the single unit dosage comprising the therapeutically effective amount of each of

linezolid, bedaquiline and pretomanid, and optionally pyrazinamide, or a pharmaceutically acceptable salt of each thereof.

Dated this 16th day of April 2018

5



DR. SANCHITA GANGULI
IN/PA No. 625
of S. MAJUMDAR & CO.
Applicant's Agent

10

We claim

1. A pharmaceutical composition, comprising a therapeutically effective amount of each of linezolid, bedaquiline, and pretomanid, and optionally pyrazinamide, or a pharmaceutically acceptable salt of each thereof, and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition as claimed in ~~according to~~ claim 1, wherein linezolid is at a dosage of 100 mg/kg.

3. The pharmaceutical composition as claimed in ~~in~~ ~~according to~~ claim 1, wherein linezolid is at a dosage of 50 mg/kg.

~~4. A method for the treatment of tuberculosis, comprising the step of administering to a patient in need thereof a therapeutically effective amount of each of linezolid, bedaquiline and pretomanid, and optionally pyrazinamide, or a pharmaceutically acceptable salt of each thereof, and a pharmaceutically acceptable carrier.~~

~~——— 5. The method according to claim 4, wherein linezolid is administered for up to one to two months at 100 mg/kg per day.~~

~~6. The method according to claim 4, wherein linezolid is administered for up to two months at 50 mg/kg per day.~~

~~——— 7. The pharmaceutical composition according to claim 1, wherein bedaquiline is at a dosage of 200 to 400 mg qd.~~

~~8. The method according to claim 4, wherein bedaquiline is administered at 400 mg qd for two weeks followed by 200 mg tiw.~~

~~9. The pharmaceutical composition according to claim 1, wherein linezolid is at dosage of 600 mg bid or 1200 mg qd.~~

~~10. The pharmaceutical composition according to claim 1, wherein pretomanid is at a dosage of 100 to 200 qd.~~

4. The pharmaceutical composition as claimed in claim 1, wherein the pharmaceutical composition is in the form of a plurality of unit dosages, the plurality of unit dosages collectively comprising the therapeutically effective amount of each of linezolid, bedaquiline and pretomanid, and optionally pyrazinamide or a pharmaceutically acceptable salt of each thereof.

5. The pharmaceutical composition as claimed in claim 1, wherein the pharmaceutical composition is in the form of a plurality of unit dosages, the plurality of unit dosages collectively comprising 600 mg or 1200 mg linezolid, 200 to 400 mg bedaquiline, 100 to 200 mg pretomanid, and optionally pyrazinamide, or a pharmaceutically acceptable salt of each thereof.

6. The pharmaceutical composition as claimed in claim 1, wherein the pharmaceutical composition is in the form of a single unit dosage, the single unit dosage comprising the therapeutically effective amount of each of linezolid, bedaquiline and pretomanid, and optionally pyrazinamide, or a pharmaceutically acceptable salt of each thereof.